Research Article
BibTex RIS Cite

Investigation of Hepatitis E Virus IgG Seroprevalence in Women with Reproductive Age

Year 2016, Volume: 7 Issue: 1, 69 - 72, 01.03.2016

Hakan Temiz Ayşe Batgi Azarkan Mehmet Obut Şeyhmus Mete

https://doi.org/10.5799/jcei.328684

Abstract

Objective: Hepatitis E virus (HEV) infection can cause fatal hepatitis particularly in pregnant women. In this study, it was
aimed to investigate the rate of anti HEV IgG seroprevalence in women of childbearing age and whether there are differences
in seroprevalence among people living in urban and rural areas or not.
Methods: A total of 158 women volunteers aged 15-49 years living in rural or urban areas were included in this study.
Anti-HEV IgG antibodies were performed with enzyme immunoassay method. The obtained data were presented as
numbers and percentages and statistically analyzed.
Results: Anti-HAV IgG was detected positive in 41 of the 158 volunteers (25.9%). Anti-HEV IgG was found positive in 25
of the 92 volunteers living in urban areas (27.2%) and in 16 of the 66 volunteers in rural areas (24.2%).
Conclusion: In our city, HEV seroprevalence is above the average in Turkey. We think that epidemiological factors
should be investigated and that screening HEV serology can be useful in pregnancy monitoring. J Clin Exp Invest 2016;
7 (1): 69-72

Keywords

HEV seroprevalence woman

References

  • 1. Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 2008;8:698-709.
  • 2. Kamar N, Bendall R, Legrand-Abravanel F, et al. Hepatitis E. Lancet 2012;379:2477-2488.
  • 3. Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. N Engl J Med 2012;367:1237-1244.
  • 4. WHO Hepatitis E. Ulaşılabileceği Adres: http://www.who. int/mediacentre/factsheets/fs280/en/
  • 5. Kırdar S. Hepatit E virus enfeksiyonu. Viral Hepatit Derg 2012;18:1-5.
  • 6. Teshale EH, Howard CM, Grytdal SP, et al. Hepatitis E epidemic, Uganda. Emerg Infect Dis 2010;16:126-129.
  • 7. Kmush B, Wierzba T, Krain L, et al. Epidemiology of hepatitis E in low and middle income countries of Asia and Africa. Semin LiverDis 2013;33:15-29.
  • 8. Velázquez O, Stetler HC, Avila C, et al. Epidemic transmission of enterically transmitted non-A, non-B hepatitis in Mexico, 1986-1987. JAMA 1990;263:3281-3285.
  • 9. Krain LJ, Nelson KE, Labrique AB. Host immunest at us and response to hepatitis E Virus infection. Clin Microbiol Rev 2014;27:139-165.
  • 10. Zhu FC, Huang SJ, Wu T, et al. Epidemiology of zoonotic hepatitis E: A community based surveillance study in a rural population in China. PLoS One 2014;9:e87154.
  • 11. Zhang J, Zhang XF, Zhou C, et al. Protection against hepatitis E Virus infection by naturally acquired and vaccineinduced immunity. Clin Microbiol Infect 2014;20:O397- O405.
  • 12. Investigation of hepatitis E outbreak among refugees-Upper Nile, South Sudan, 2012–2013. MMWR Morb Mortal Wkly Rep 2013;62:581-6. Ulaşılabileceği Adres: http:// www.cdc.gov/mmwr/pdf/wk/mm6229.pdf
  • 13. Zhang J,Zhang X F, Huang S J, et al. Long-term efficacy of a hepatitis E vaccine. N Engl J Med 372;10:912-922
  • 14. Aygen B. Hepatit E virusu. In: Wilke Topçu A, Söyletir G, Doğanay M. İnfeksiyon Hastalıkları ve Mikrobiyolojisi. Nobel Tıp Kitabevleri. 2. baskı. İstanbul 2002:1400-1404.
  • 15. Wedermeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis E Virus infection. Gastroenterology 2012;142:1388-13897.
  • 16. Khuroo MS. Discovery of hepatitis E: the epidemic non-A, non-B hepatitis 30 years down the memory lane. Virus Res 2011;161:3-14.
  • 17. Yazgı H, Kadanalı A, Ertek M, Gülen A. Gebelerde Hepatit E Seroprevalansı. Viral Hepatit Dergisi 2003;8:40-42.
  • 18. Aktaş AE, Yiğit N, Ayyıldız A, Yılmaz N. Atatürk Üniversitesi Diş Hekimliği Fakültesi çalışanlarında Anti HAV ve Anti HEV seroprevalansı. Viral Hepat J 2000;6:113-115.
  • 19. Erdurak FO, Dündar İH, Saltoğlu N, ve ark. Subtropik bir bölge olan Adana yöresinde anti-HEV sıklığı. II. Ulusal Viral Hepatit Sempozyumu. Ankara, 1994. Program Kitabı, s. 146.
  • 20. Gültekin M, Öğünç D, Çolak D. Sağlık personelinde HEV seroprevalansı. II. Ulusal Viral Hepatit Sempozyumu. Ankara, 1994. Program Kitabı, s. 148.
  • 21. Uçar E, Çetin M, KuvandıkM, ve ark. Hatay’da hemodiyaliz tedavisi alan hastalarda hepatit e virus seropozitifliği. Mikrobiyol Bul 2009;43:299-302.
  • 22. Olcay D, Eyigün CP, Özgüven ŞV, et al. Anti-HEV antibody prevalence in three distinct regions of Turkey and its relationship with age, gender, education and abortions. Turk J Med Sci.33;2003:33-38.
  • 23. Aydın K, Koksal I, Çaylan R, ve ark. Hepatit E seropozitifliğinin iki bölgede araştırılması. II.Ulusal Viral Hepatit Sempozyumu. Ankara, 1994. Program Kitabı, s. 151.
  • 24. Ceylan A, Ertem M, Özekinci T, İlçin E. Atık Suların Tarımda arıtılmadan kullanıldığı Diyarbakır Hevsel bahçelerinde çalışanlarda hepatit-e. Viral Hepat J 2000;6:98-101.

Year 2016, Volume: 7 Issue: 1, 69 - 72, 01.03.2016

Hakan Temiz Ayşe Batgi Azarkan Mehmet Obut Şeyhmus Mete

https://doi.org/10.5799/jcei.328684

Abstract

References

  • 1. Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 2008;8:698-709.
  • 2. Kamar N, Bendall R, Legrand-Abravanel F, et al. Hepatitis E. Lancet 2012;379:2477-2488.
  • 3. Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. N Engl J Med 2012;367:1237-1244.
  • 4. WHO Hepatitis E. Ulaşılabileceği Adres: http://www.who. int/mediacentre/factsheets/fs280/en/
  • 5. Kırdar S. Hepatit E virus enfeksiyonu. Viral Hepatit Derg 2012;18:1-5.
  • 6. Teshale EH, Howard CM, Grytdal SP, et al. Hepatitis E epidemic, Uganda. Emerg Infect Dis 2010;16:126-129.
  • 7. Kmush B, Wierzba T, Krain L, et al. Epidemiology of hepatitis E in low and middle income countries of Asia and Africa. Semin LiverDis 2013;33:15-29.
  • 8. Velázquez O, Stetler HC, Avila C, et al. Epidemic transmission of enterically transmitted non-A, non-B hepatitis in Mexico, 1986-1987. JAMA 1990;263:3281-3285.
  • 9. Krain LJ, Nelson KE, Labrique AB. Host immunest at us and response to hepatitis E Virus infection. Clin Microbiol Rev 2014;27:139-165.
  • 10. Zhu FC, Huang SJ, Wu T, et al. Epidemiology of zoonotic hepatitis E: A community based surveillance study in a rural population in China. PLoS One 2014;9:e87154.
  • 11. Zhang J, Zhang XF, Zhou C, et al. Protection against hepatitis E Virus infection by naturally acquired and vaccineinduced immunity. Clin Microbiol Infect 2014;20:O397- O405.
  • 12. Investigation of hepatitis E outbreak among refugees-Upper Nile, South Sudan, 2012–2013. MMWR Morb Mortal Wkly Rep 2013;62:581-6. Ulaşılabileceği Adres: http:// www.cdc.gov/mmwr/pdf/wk/mm6229.pdf
  • 13. Zhang J,Zhang X F, Huang S J, et al. Long-term efficacy of a hepatitis E vaccine. N Engl J Med 372;10:912-922
  • 14. Aygen B. Hepatit E virusu. In: Wilke Topçu A, Söyletir G, Doğanay M. İnfeksiyon Hastalıkları ve Mikrobiyolojisi. Nobel Tıp Kitabevleri. 2. baskı. İstanbul 2002:1400-1404.
  • 15. Wedermeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis E Virus infection. Gastroenterology 2012;142:1388-13897.
  • 16. Khuroo MS. Discovery of hepatitis E: the epidemic non-A, non-B hepatitis 30 years down the memory lane. Virus Res 2011;161:3-14.
  • 17. Yazgı H, Kadanalı A, Ertek M, Gülen A. Gebelerde Hepatit E Seroprevalansı. Viral Hepatit Dergisi 2003;8:40-42.
  • 18. Aktaş AE, Yiğit N, Ayyıldız A, Yılmaz N. Atatürk Üniversitesi Diş Hekimliği Fakültesi çalışanlarında Anti HAV ve Anti HEV seroprevalansı. Viral Hepat J 2000;6:113-115.
  • 19. Erdurak FO, Dündar İH, Saltoğlu N, ve ark. Subtropik bir bölge olan Adana yöresinde anti-HEV sıklığı. II. Ulusal Viral Hepatit Sempozyumu. Ankara, 1994. Program Kitabı, s. 146.
  • 20. Gültekin M, Öğünç D, Çolak D. Sağlık personelinde HEV seroprevalansı. II. Ulusal Viral Hepatit Sempozyumu. Ankara, 1994. Program Kitabı, s. 148.
  • 21. Uçar E, Çetin M, KuvandıkM, ve ark. Hatay’da hemodiyaliz tedavisi alan hastalarda hepatit e virus seropozitifliği. Mikrobiyol Bul 2009;43:299-302.
  • 22. Olcay D, Eyigün CP, Özgüven ŞV, et al. Anti-HEV antibody prevalence in three distinct regions of Turkey and its relationship with age, gender, education and abortions. Turk J Med Sci.33;2003:33-38.
  • 23. Aydın K, Koksal I, Çaylan R, ve ark. Hepatit E seropozitifliğinin iki bölgede araştırılması. II.Ulusal Viral Hepatit Sempozyumu. Ankara, 1994. Program Kitabı, s. 151.
  • 24. Ceylan A, Ertem M, Özekinci T, İlçin E. Atık Suların Tarımda arıtılmadan kullanıldığı Diyarbakır Hevsel bahçelerinde çalışanlarda hepatit-e. Viral Hepat J 2000;6:98-101.
There are 24 citations in total.

Details

Subjects Health Care Administration
Journal Section Research Article
Authors

Hakan Temiz This is me

Ayşe Batgi Azarkan This is me

Mehmet Obut

Şeyhmus Mete This is me

Publication Date March 1, 2016
Published in Issue Year 2016 Volume: 7 Issue: 1

Cite

APA Temiz, H., Azarkan, A. B., Obut, M., Mete, Ş. (2016). Investigation of Hepatitis E Virus IgG Seroprevalence in Women with Reproductive Age. Journal of Clinical and Experimental Investigations, 7(1), 69-72. https://doi.org/10.5799/jcei.328684
AMA Temiz H, Azarkan AB, Obut M, Mete Ş. Investigation of Hepatitis E Virus IgG Seroprevalence in Women with Reproductive Age. J Clin Exp Invest. March 2016;7(1):69-72. doi:10.5799/jcei.328684
Chicago Temiz, Hakan, Ayşe Batgi Azarkan, Mehmet Obut, and Şeyhmus Mete. “Investigation of Hepatitis E Virus IgG Seroprevalence in Women With Reproductive Age”. Journal of Clinical and Experimental Investigations 7, no. 1 (March 2016): 69-72. https://doi.org/10.5799/jcei.328684.
EndNote Temiz H, Azarkan AB, Obut M, Mete Ş (March 1, 2016) Investigation of Hepatitis E Virus IgG Seroprevalence in Women with Reproductive Age. Journal of Clinical and Experimental Investigations 7 1 69–72.
IEEE H. Temiz, A. B. Azarkan, M. Obut, and Ş. Mete, “Investigation of Hepatitis E Virus IgG Seroprevalence in Women with Reproductive Age”, J Clin Exp Invest, vol. 7, no. 1, pp. 69–72, 2016, doi: 10.5799/jcei.328684.
ISNAD Temiz, Hakan et al. “Investigation of Hepatitis E Virus IgG Seroprevalence in Women With Reproductive Age”. Journal of Clinical and Experimental Investigations 7/1 (March 2016), 69-72. https://doi.org/10.5799/jcei.328684.
JAMA Temiz H, Azarkan AB, Obut M, Mete Ş. Investigation of Hepatitis E Virus IgG Seroprevalence in Women with Reproductive Age. J Clin Exp Invest. 2016;7:69–72.
MLA Temiz, Hakan et al. “Investigation of Hepatitis E Virus IgG Seroprevalence in Women With Reproductive Age”. Journal of Clinical and Experimental Investigations, vol. 7, no. 1, 2016, pp. 69-72, doi:10.5799/jcei.328684.
Vancouver Temiz H, Azarkan AB, Obut M, Mete Ş. Investigation of Hepatitis E Virus IgG Seroprevalence in Women with Reproductive Age. J Clin Exp Invest. 2016;7(1):69-72.